Abstracts tagged "Managed Care"

Abstract Number: 0677 • ACR Convergence 2024
Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Gulsen Ozen¹, Sofia Pedro², Kaleb Michaud³ and Robyn Domsic⁴, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…
Abstract Number: 1456 • ACR Convergence 2024
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Lija James¹, Elnaz Saeedi², Jean-Guillaume Letarouilly¹, Nicola Gullick³, Anne Francis², Deepak Jadon⁴, William Tillett⁵, Yvonne Sinomati², Laura Tucker¹, Nadia Mian², Ines Rombach², Ioana Marian², Maria Sofia Massa² and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁴Cambridge University, Cambridge, United Kingdom, ⁵Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁶University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic musculoskeletal disease, which can lead to progressive joint pain, joint destruction, and loss of function. Evidence suggests that…
Abstract Number: 2558 • ACR Convergence 2024
Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand
Patapong Towiwat¹, Wichittra Tassaneeyakul², Suppachai Lawanaskol³, Chonlaphat Sukasem⁴, Nontaya Nakkam², Ticha Rerkpattanapipat⁴, Jettanong Klaewsongkram⁵, Pawinee Rerknimitr⁵, Duangkamon Poolpun⁶, Worawit Louthrenoo⁷ and Niwat Saksit⁸, ¹Naresuan university, Phitsanulok, Thailand, ²Khon Kaen university, Khon Kaen, Thailand, ³Chaiprakan hospital, Chiang Mai, Thailand, ⁴Mahidol university, Bangkok, Thailand, ⁵Chulalongkorn university, Bangkok, Thailand, ⁶Buddhachinaraj hospital, Phitsanulok, Thailand, ⁷Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁸Phayao university, Phayao, Thailand
Background/Purpose: Severe allopurinol hypersensitivity (SAH), although uncommon, is a serious adverse event of allopurinol. Both genetic (HLA-B*58:01) and non-genetic factors (female gender, age ≥60-65 years,…
Abstract Number: PP02 • ACR Convergence 2023
Patient Centered Care: The Complete Picture
Chisa Nosamiefan, South Weymouth, MA
Background/Purpose: My recollection is that in I997 there about, I began to feel sick and I experienced these symptoms, night sweats, pain in my chest,…
Abstract Number: 2404 • ACR Convergence 2023
Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk
Eugenio De Miguel¹, Rositsa Karalilova², PIERLUIGI MACCHIONI³, Cristina Ponte⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Sara Monti⁷, Irene Monjo¹, Zguro Batalov², Giulia Klinowski⁸, Paolo Falsetti⁹, David Kane¹⁰, Corrado Campochiaro¹¹ and Alojzija Hocevar¹², ¹Hospital Universitario La Paz, Madrid, Spain, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁸IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁹San Raffaele Scientific Institute, Siena, Italy, ¹⁰Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ¹²Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: 0795 • ACR Convergence 2021
Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis
Michal Doumen¹, Diederik De Cock¹, Sofia Pazmino¹, Delphine Bertrand¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Self-efficacy (SE), or patients’ confidence in their ability to control disease and its consequences, was recently prioritised in EULAR-recommendations for self-management strategies for inflammatory…
Abstract Number: 1024 • ACR Convergence 2021
Medical Care Seeking Is Frequent and Associated with Overuse of Low-Value Care for Low Back Pain in Portugal: Results from a Nationwide Population-Based Study
Luís Antunes Gomes¹, Eduardo Brazete Cruz², Ana Rita Henriques¹, Jaime Branco³, Helena Canhão⁴ and Ana Maria Rodrigues³, ¹EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ²Comprehensive Health Research Centre (CHRC), Setubal, Portugal, ³EpiDoC Unit, CEDOC, Nova Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ⁴EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisboa, Portugal
Background/Purpose: Low back pain (LBP) constitutes an important cause of disability and morbidity in general population. Appropriate care for LBP includes non-pharmacological interventions based on…
Abstract Number: 1072 • ACR Convergence 2021
The Multidisciplinary Approach with Patient Collaboration Improve the Clinical Effectiveness of the Intervention
Carlos González¹, Luis Menchén-Viso¹, Ofelia Baniandres-Rodriguez¹, Carmen Lobo-Rodríguez¹, Ana Herranz-Alonso¹, Ignacio Marín-Jiménez¹, Juan Carlos Nieto², Lucia Ibares-Frias¹, Indalecio Monteagudo¹, Esther Chamorro de Vega¹, Javier Torresano-Bruno¹, Amparo Lopez-Esteban¹, Arantza Ais-Larisgoitia¹, Paloma Morales de los Ríos Luna¹, ana Lopez-Calleja¹, Sonia Garcia de San Jose³ and Jose Maria Alvaro-Gracia³, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Maranón, Madrid, Spain
Background/Purpose: We have developed a multidisciplinary unit for patients in treatment with biological therapies (BT) with the collaboration of Dermatology (Der), Gastroenterology (GE), Rheumatology (Rheu),…
Abstract Number: 1600 • ACR Convergence 2021
Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?
Samon Oomen-Lochtefeld¹, Rochelle Tsemekhin², Lori Lyn Price², Chen Guang³ and Chenchen Wang², ¹Tufts University, Boston, MA, ²Tufts Medical Center, Boston, MA, ³Harvard Medical School, Boston, MA
Background/Purpose: The management of the patients with chronic conditions such as musculoskeletal pain can be affected by the COVID-19 pandemic. However, the impact of COVID-19…
Abstract Number: 0145 • ACR Convergence 2020
Treat-to-Target in Rheumatoid Arthritis: Rates of Treatment Changes in Patients Engaged with Care Management Services Compared to Historically Reported National Registry Based Estimates
Pranav Patel¹, Andrew Krueger², Aliza Lipson³, Michele Hamburger⁴ and Craig Hunter⁵, ¹CVS Health, Toledo, OH, ²Accordant Health Services, Greensboro, NC, ³Emory University, Palmetto Bay, FL, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Northbrook
Background/Purpose: Treat-to-target is the foundation of rheumatoid arthritis (RA) management. Prioritizing routine measurement of patient-reported disease activity along with conventional physician, laboratory and imaging assessments…
Abstract Number: 0643 • ACR Convergence 2020
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Carlos González¹, Luis Menchén¹, Indalecio Monteagudo¹, Ofelia Baniandrés², Juan Carlos Nieto Gonzalez¹, Ignacio Marín-Jiménez¹, Ana Herranz-Alonso¹, Carmen Lobo-Rodríguez¹, Amparo López-Esteban¹, Ana López¹, Arantza Ais-Larisgoitia¹, Esther Chamorro de Vega¹, Paloma Morales de los Ríos¹, Maria Jesús Lizcano¹, Jose Maria Alvaro-Gracia¹ and Sonia García de San-José¹, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
Background/Purpose: To analyze the risk of admission for COVID19 infection and outcome of patients treated with b/tsDMARD from our center, to compare with all patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].